Montair-ODT 4 mg tablet is an orally disintegrating tablet. Do not open the sachet until you are ready to use it. Once opened, place the entire tablet directly on your tongue. It will rapidly disintegrate and can be swallowed with your saliva. No water is needed. Take it once daily in the evening, with or without food.

Montelukast is a selective and orally active leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells, including mast cells and eosinophils, and are associated with the pathophysiology of asthma and allergic rhinitis. By blocking these receptors, montelukast inhibits bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment, thereby reducing inflammation and improving respiratory function.

• •Hypersensitivity to Montelukast or any component of the formulation.
• •Acute asthma attacks (not indicated for reversal of bronchospasm in acute asthma).

Store below 30°C (86°F) in a dry place, protected from light and moisture. Keep out of reach of children.

In post-marketing experience, there have been reports of acute overdose with montelukast. The most frequently reported adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Treatment is symptomatic and supportive. It is not known if montelukast is dialyzable by peritoneal or hemodialysis.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. It is unknown whether montelukast is excreted in human milk. Exercise caution when administering to a nursing mother.